Dimensional Fund Advisors LP Boosts Holdings in Pacira BioSciences, Inc. $PCRX

Dimensional Fund Advisors LP boosted its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 5.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,060,597 shares of the company's stock after buying an additional 110,584 shares during the period. Dimensional Fund Advisors LP owned approximately 5.24% of Pacira BioSciences worth $46,572,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. lifted its stake in Pacira BioSciences by 5,900.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,500 shares of the company's stock valued at $39,000 after acquiring an additional 1,475 shares during the period. Kestra Advisory Services LLC acquired a new position in shares of Pacira BioSciences in the fourth quarter worth about $48,000. Eurizon Capital SGR S.p.A. acquired a new position in shares of Pacira BioSciences in the fourth quarter worth about $51,000. Global Retirement Partners LLC boosted its stake in shares of Pacira BioSciences by 479.4% during the 4th quarter. Global Retirement Partners LLC now owns 2,028 shares of the company's stock worth $52,000 after acquiring an additional 1,678 shares in the last quarter. Finally, Hantz Financial Services Inc. boosted its stake in shares of Pacira BioSciences by 127.3% during the 4th quarter. Hantz Financial Services Inc. now owns 2,573 shares of the company's stock worth $67,000 after acquiring an additional 1,441 shares in the last quarter. 99.73% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, SVP Lauren Riker sold 6,115 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $23.50, for a total transaction of $143,702.50. Following the completion of the sale, the senior vice president owned 62,284 shares in the company, valued at approximately $1,463,674. This represents a 8.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.40% of the stock is currently owned by corporate insiders.

Pacira BioSciences Price Performance

Pacira BioSciences stock opened at $26.41 on Monday. The company has a current ratio of 4.73, a quick ratio of 3.35 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $1.04 billion, a P/E ratio of 220.10 and a beta of 0.27. The stock's fifty day simple moving average is $24.46 and its 200-day simple moving average is $23.24. Pacira BioSciences, Inc. has a twelve month low of $18.80 and a twelve month high of $27.64.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported $0.60 earnings per share for the quarter, missing analysts' consensus estimates of $0.61 by ($0.01). Pacira BioSciences had a net margin of 0.70% and a return on equity of 10.24%. The firm had revenue of $177.38 million during the quarter, compared to analyst estimates of $171.80 million. During the same quarter in the previous year, the business posted $0.65 earnings per share. Pacira BioSciences's revenue for the quarter was up 5.0% compared to the same quarter last year. As a group, equities analysts expect that Pacira BioSciences, Inc. will post 1.94 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on PCRX shares. Needham & Company LLC lifted their price target on Pacira BioSciences from $30.00 to $32.00 and gave the company a "buy" rating in a research note on Friday, May 1st. Weiss Ratings raised shares of Pacira BioSciences from a "sell (d)" rating to a "sell (d+)" rating in a research note on Wednesday, May 20th. HC Wainwright reiterated a "buy" rating and set a $38.00 price objective on shares of Pacira BioSciences in a research note on Wednesday, July 1st. Zacks Research upgraded shares of Pacira BioSciences from a "strong sell" rating to a "hold" rating in a research report on Tuesday, April 7th. Finally, Royal Bank Of Canada boosted their price target on shares of Pacira BioSciences from $22.00 to $24.00 and gave the company a "sector perform" rating in a research report on Friday, May 1st. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $29.40.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company's flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.